Human papillomavirus (HPV) vaccine is efficacious but the real-life effectiveness of gender-neutral and girls-only vaccination strategies is unknown. We report a community-randomized trial on the protective effectiveness [(PE) 5 vaccine efficacy (VE) 1 -herd effect (HE)] of the two strategies among females in virtually HPV vaccination na€ ıve population. We randomized 33 Finnish communities into Arm A) gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (11 communities), Arm B) HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (11 communities) or Arm C) gender-neutral HBV vaccination (11 communities). All resident 39,420 females and 40,852 males born 1992-95 were invited in 2007-09. Virtually all (99%) 12-to 15-year-old participating males (11,662) and females (20,513) received three doses resulting in uniform 20-30% male and 50% female vaccination coverage by birth cohort. Four years later (2010-14) 11,396 cervicovaginal samples obtained from 18.5 year-old women were tested for HPV DNA, and prevalence of cervical HPV infections by trial arm and birth cohort was the main outcome measure. VEs against HPV16/18 varied between 89.2% and 95.2% across birth cohorts in arms A and B. The VEs against non-vaccine types consistent with cross-protection were highest in those born 1994-95 for HPV45 (VE A 82.8%; VE B 86.1%) and for HPV31 (VE A 77.6%, VE B 84.6%). The HEs in the non HPV-vaccinated were statistically significant in those born 1994-95 for HPV18 (HE A 51.0%; HE B 47.2%;.2) and for HPV31/33 in arm A (HE A 53.7%; 22.1-72.5). For HPV16 and 45 no significant herd effects were detected. PE estimates against HPV16/18 were similar by both strategies (PE A 58.1%; 45.1-69.4; PE B 55.7%; 42.9-66.6). PE estimates against HPV31/33 were higher by the gender-neutral
vaccination (PE A 60.5%; 43.6-73.4; PE B 44.5%; 24.9-60.6). In conclusion, while gender-neutral strategy enhanced the effectiveness of HPV vaccination for cross-protected HPV types with low to moderate coverage, high coverage in males appears to be key to providing a substantial public health benefit also to unvaccinated females. Trial registration www.clinicaltrials.gov. com NCT000534638
Oncogenic human papillomaviruses (HPVs) cause up to 1% and 9% of cancers in males and females. 1 Prophylactic vaccines against the most oncogenic HPV types 16 and 18 were licensed 10 years ago 2, 3 and can now protect against 90% of the most stringent HPV-associated pre-cancer end-points in females. 4 High vaccine efficacy (VE) has been shown also in males. 5 Implementation of a vaccine into a vaccination program requires that safety, immunogenicity and vaccine efficacy are demonstrated in clinical trials. Mathematical models have been used to simulate the impact of girls-only versus genderneutral vaccination strategies, and focused on cost-effectiveness. 6 Due great expectations on girls-only vaccination coverage and not complete accounting of total HPV disease burden the girls-only strategy has dominated. 7 Recently two girls-only HPV vaccination programs with 90 and 70% coverage reported substantial herd effects (HEs) against HPV16 and 6/11. 8, 9 Mostly the coverage has, however, been low, about 50%. 9, 10 Basic reproduction numbers (R0) of most HPV types are low to moderate (1.4 to 4.0), 11 but the prevalence rates of genital HPVs are high, 8, 9, 12 and associated sexual risk-taking behavior is assortative. 12, 13 Thus, the HE could play an important role even if the vaccination coverage is low. 13 Globally, HPV vaccination coverage is moderate at the best, and recent models have shown gender-neutral likely to be more effective where coverage is moderate or low. [14] [15] [16] This has already been implemented in some countries, although empirical HE and protective effectiveness (PE) estimates based on randomized trials are missing.
In 2007-2009 a community-randomized trial among 80,272 adolescents 12 was launched to assess real-life protective effectiveness (PE 5 VE 1 HE) of gender-neutral or girlsonly HPV vaccination strategies. We present here results of the GSK-sponsored HPV-040 trial (NCT00534638) to find out to what extent gender-neutral vaccination improves the magnitude of overall protective effectiveness compared to girls-only vaccination. Our trial was conducted in the absence of notable opportunistic HPV vaccination and before implementation of a national HPV vaccination program.
Material and Methods

Stratified randomization of study communities
Originally the 33 communities were randomized into three study arms, 11 in each arm. All communities had >35,000 inhabitants and were located at 50 km distance (35 km in southern Finland) from each other. Basic infection rates assuming a steady state of HPV16/18 epidemics in Finland, 17 were estimated using HPV16/18 seroprevalence (cumulative incidence) rates measured in samples of 50 randomly selected <23 year-old women per community. 12 Before randomization, the 33 communities were stratified into comparable numbers of low (<20.5%, 12 communities), intermediate (20.5-24%, nine communities) and high (>24%, 12 communities) seroprevalence categories to maximize study power. 12 
Study conduct
The Finnish Population Register Centre was used to identify all 80,272 residents in the 33 communities, born 1992-1995, and to follow their residential history throughout the studyperiod. In 2007-2009 invitation letters were sent to the parents or legal guardians. The letters included information about the trial, a consent form and a prepaid envelope for consent. The first study visit took place at the school health care facilities of 250 municipal junior high schools. In Arm A, both female and male participants were randomly assigned to receive Cervarix V R (AS04-HPV-16/18) -vaccine (90%) or Engerix TM B (hepatitis B-virus, HBV) vaccine (10% to ensure estimation of the herd effect) by the SBIR system provided by GlaxoSmithKline Biologicals SA. In Arm B, females were randomly assigned to receive AS04-HPV-16/18-vaccine (90%) or HBV-vaccine (10%). In Arm B and C communities, respectively, all males and both genders of participants were assigned to receive HBV-vaccine. The remaining two doses (at Months 1 and 6) were given to 99% of all participants.
What's new?
Vaccines against cancer-causing human papillomaviruses (HPVs) effectively prevent HPV infection. However, whether it is better in terms of health and cost to vaccinate only girls or to vaccinate both boys and girls remains unclear. The present report details the results of a community-randomized trial of the two strategies in an HPV vaccination-na€ ıve population born between 1992 and 1995 in Finland. Overall, low-to moderate-coverage gender-neutral vaccination provided the greatest protection against HPV. Gender-neutral vaccination of early adolescents was associated with significant herd effects and cross-protection against a number of non-vaccine HPV types.
The randomized participants: Arm A females and males and Arm B females were blinded. The blinding was maintained until the age of 18.5 years. At the age 18.5 all vaccinated/unvaccinated female residents of the study site communities born 1992-95 were invited to attend follow-up and cross-vaccination, with either HBV-vaccine or AS04-HPV-16/18-vaccine they had not received, at the University of Tampere study sites in the 33 communities, during 2010-2014. A cervical sample taken by study nurse, and a self-collected cervicovaginal sample for HPV testing were obtained.
All female participants to the follow-up consented to participate in a Chlamydia trachomatis screening trial and filled a questionnaire on demographic information, behavior, and sexual health.
PCR analysis
All self-collected samples were analyzed by PCR, with HPV typing, using matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry for detection of HPV6/11/16/ 18/31/33/35/39/45/51/52/56/58/59/66/68. 18 The PCR used the MGP consensus primers followed by a mass extension reaction with type-specific primers that each have a unique molecular weight for a specific type. 18 When the mass extension reaction is completed, unextended primers demonstrate the absence and extended primers show the presence of each specific genotype. Due to a cross-reaction between the primer for HPV11/89 and between the primers for HPV68/70, confirmative testing was performed on all positives for HPV11/68 using Luminex platform. 18 
Statistical analyses
To determine the VE in HPV-versus HBV-vaccinated women, 1-RR of HPV infection (HPV DNA positivity) was estimated for Arm A versus Arm C, and Arm B versus Arm C by the Generalized Estimating Equation (GEE) method (binomial response and logit link was applied). An exchangeable correlation structure between responses (HPV results) of women from the same community, and independence between responses of women from different communities were assumed. The 95% confidence intervals (95% CI) were based on the profile likelihood.
Two separate dynamic transmission models 15, 16 calibrated to Finnish data were used to estimate the HE as the relative reduction of HPV prevalence among non-HPV16/18 vaccinated girls in Arm A and Arm B compared to the non-HPV16/18 vaccination strategy in Arm C. Both models predicted delays in the HE so that HPV prevalence in the 1994-95 cohorts was lower than in the 1992-93 cohorts, both among non-vaccinated and vaccinated women. 12 For the HE, the prevalence rates between arms were compared in line with the a priori made Report Analysis Plan. To determine HE in non-vaccinated women, 1-RR of HPV DNA positivity were estimated for Arm A versus Arm C, and Arm B versus Arm C by the GEE modeling using SAS 9.4 (SAS Inst.., Cary, NC).
The VE and HE estimates were adjusted at the individual level for C.trachomatis positivity, used as a surrogate to control for heterogeneity in risk-taking behavior between the communities, or different risk-taking behavior between vaccinated and unvaccinated women, respectively. Adjustment at the community level was performed for smoking (questionnaire-based >25% community prevalence of current active, at least weekly, smoking at the age of 18.5 years as compared to <25% community prevalence), a surrogate for poor health behavior, and for HPV vaccination coverage (0% aliased, reference class 0%<-<50%, 50%-<55%, >551%) (for HE only). In addition, mobility was adjusted for by a variable consisting of both individual-and community-level aspects: moving between communities in the same arm or between arm A and B communities and/or living in semi-urban community.
For the HE estimation the different ratio between HBVvaccinated and unvaccinated in Arm C as compared with Arms A and B was corrected: Twenty-one random samples were selected from each 44 community-birth year strata of HBV vaccinated Arm C women. For each random sample HBV vaccinated women were sampled with rate 0.125 in each strata, equalizing the HBV-vaccinated -unvaccinated ratio in Arm C with Arms A and B, and HE was estimated by representing Arm C by all unvaccinated women and sampled HBV vaccinated women. The reported HE estimates are exponential means of 21 random sample-specific estimates, HE 5100 12exp 1 21
The 95% CI were estimated using the entire study population (Appendix). The prevalence rates in Arm C reported are means of 21 random sample specific estimates.
As a sensitivity analysis for the HEs we compared reduction rates of HPV prevalence between the 1992-93 and 1994-95 cohorts within arms. Models suggest that such reductions between these vaccinated cohorts exist and set a lower bound for actual HEs. 12 We used a weighted version of the Woolf estimator instead of the Mantel-Haenszel estimator due to its more reliable confidence interval when dealing with a restricted number of strata. 19, 20 It was calculated weighting logarithms of stratum-specific odds ratios, including intracluster correlation in the weights. Two independent approaches based on community-specific relative changes of prevalence were also used (weighted community-specific estimate, Bayesian estimate, Appendix). The latter two methods consider individual communities as mini-trials combined by study arms. The PE of HPV vaccination in total population was determined by combining vaccination effectiveness among HPV-vaccinated women (VE including herd effect) and the HE in non-HPV vaccinated women. The vaccination effectiveness was weighted by HPV vaccination coverage, and the HE by 1 -coverage.
Results
Recruitment and follow-up of the participants
Enrolment of 20,513 females (51-53% participation rate by arm) and 11,662 males (22-32% participation rate by arm) was virtually uniform by birth cohort throughout the recruitment period Q4/2007-Q1/2010. 12 Cervico-vaginal HPV DNA data were obtained for 11,396 (98.3%) of 11,589 females sampled at the follow-up visit out of the 46,128 invited 18.5 year-old females, including a large group (1,836) of non-HPV16/18 vaccinated females (Fig. 1) . By residential history 92 women had moved between control and intervention communities and were excluded. Age at sexual debut was similar in all arms. In Arm A somewhat more non-HPV vaccinated women had had more life-time partners and were current smokers compared to Arms B/C (Table 1) . At the time of the follow-up visit, 83-93% of vaccinated women lived in the study communities as opposed to 77-83% of unvaccinated women.
In the Arm A and B communities the numbers of unvaccinated women participating at age 18.5 were 1.7-times the HBV vaccinated 1992-95 born women participating at age 12 to 15. On the contrary, in the Arm C communities there were fivefold HBV vaccinated participants compared to unvaccinated participants attending at age 18.5 ( Fig. 1) . This implicated the sample fraction of 0.125 for HBV vaccinated in Arm C to balance the proportions of the HBV vaccinated and unvaccinated participants.
Direct HPV vaccine efficacy
The VE against the vaccine types HPV16 and HPV18 ranged from 91% to 97%, and against HPV types 31, 33 and 45 from 43% to 86% (Table 2 ). The point estimates for HPV types 31, 33 and 45 tended to increase to the youngest birth cohorts (Table 2 ). In 1994-95 born, the HPV31 and HPV45 VEs were only slightly lower than VEs against HPV16 or HPV18 (Table 2) .
Herd effect against vaccine HPV types 16/18
When the vaccination coverage in males was 20.0% and 45.0% to 47.5% in females our two models predicted 3.9 to 9.7% reduction in HPV16 prevalence rates in arms A and B for the non-HPV vaccinated female 1994-95 birth cohorts compared to the 1992-93 cohorts. However, the observed HPV16 prevalence rates tended to increase in the 1994-95 birth cohorts as compared to the 1992-93 birth cohorts, and the observed HPV16 HE-estimates were low and not significant for the 1994-95 birth cohorts: HE A 22.5% and HE B 15.7% (Table 3) .
Our models predicted 5.9 to 10.5% reduction in HPV18 prevalence within arms A and B for the non-HPV vaccinated female 1994-95 birth cohorts compared to the 1992-93 cohorts. High (47-49%) HPV18 prevalence reductions were observed when comparing these birth cohorts both in Arms A and B (Table 3 ). Seven of 11 Arm A communities, and 5 of 11 Arm B communities showed prevalence reduction. Both for Arms A and B the observed HPV18 HE estimates in the 1994-95 born were significant HE A 51.0% (95% CI 8.3-73.8) and HE B 47.2% (95% CI 6.5-70.2).
Herd effect against cross-protected high-risk HPV types
In the non-HPV vaccinated women, 45% mean prevalence reduction for HPV31/33 between birth cohorts 1992-93 and 1994-95 was observed in the Arm A (Table 3 ). This was visualized by maps displaying the prevalence reduction in a majority of the Arm A communities (9 of 11; Fig. 2a ). In the Arm A versus Arm C comparison high to moderate HE estimates for HPV31, 33 and 31/33 were observed in the 1994-95 born (HE A 66.0%, 39.1% and 53.7%; Table 3 ). In contrast, neither birth cohort-specific (1992-93 vs. 1994-95) HPV31/33 prevalence reduction in Arm B nor notable HPV31/33 HEs in the comparison of Arm B versus Arm C were observed (Table 3 , Figs. 2b and 2c) . Comparing trial arm-specific HEs of HPV31/ 33 prevalence reduction by birth cohort supported the GEEestimated observations (Appendix). No HEs and wide confidence intervals reflected low HPV45 numbers in all arms. 
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Overall impact of vaccination against vaccine HPV types 16/18
Because of moderate vaccine coverage among women there were approximately equal proportions of HPV16/18 vaccinated and non-HPV vaccinated women determining overall protective effectiveness. While the overall HPV16 prevalence rates tended to increase by birth cohort, both in arms A and B those born 1994-95 had 46 and 48% lower overall HPV18 prevalence than those born 1992-93 (Table 4) . However, against all the HPV16 and HPV18 prevalence end-points the overall PE estimates of gender-neutral (Arm A) and girlsonly (Arm B) vaccination strategies were significant (Table  4 ). No differences in the overall protective effectiveness estimates between the gender-neutral and girls-only vaccination strategies were observed for HPV16/18 (PE A 58.1%, 95% CI: 45.1-69.4; PE B 55.7%, 95% CI: 42.9-66.6, Table 4 ).
Overall impact of vaccination against cross-protected highrisk HPV types
In the 1994-95 born, the overall PE estimate of the genderneutral vaccination strategy against the non-vaccine HPV31/ 33 (PE A 60.5%, 95% CI: 43.6-73.4) was 33% higher than that of the girls-only vaccination strategy (PE B 44.5% (95% CI: 24.9-60.6; Table 4 ). The Arm A HPV31, HPV33 and HPV31/33 PE estimates were all significant and close to the corresponding HPV16 and HPV18 PE estimates (Table 4) , also by various sensitivity analyses (Appendix). For HPV45 PE the girls-only (Arm B) PE estimate was significant in the 1994-95 born (Table 4 ).
Discussion
Results of our community-randomized trial on the impact of HPV vaccination on the herd effect and overall protective effectiveness support gender-neutral vaccination when low to moderate vaccination coverage and cross-protection apply, but high coverage in males appears to be key to providing a substantial public health benefit to females. To assess the impact of gender-neutral versus girls-only HPV vaccination strategies a community-randomized trial was launched ten years ago instead of a national vaccination program. Until 2013/2014, when the national HPV vaccination program got started in Finland, HPV vaccination among adolescents was negligible (<0.5%). The newly licensed HPV16/18 vaccine was proven to be safe also in this trial. 21 Furthermore, use of a beneficial HBV control vaccine and cross-vaccination at study end ensured that no harm was caused.
The population-based randomization was generally successful, 12 but we did not succeed in fully controlling for background HPV prevalence rates by randomization. Thus, we VE estimates were adjusted for C.trachomatis PCR prevalence, mobility and prevalence of current active smoking (<25%,251%). 3 Not adjusted for C.trachomatis.
adjusted for C. trachomatis positivity (a surrogate for risktaking behavior), for smoking (a surrogate of poor health conscience), and for mobility and urban versus semi-urban status. Adjusting for vaccination coverage was a priori planned to control the impact of its possible heterogeneity on the herd effect. Excellent vaccine efficacy against the vaccine HPV type infections was demonstrated in our trial with prevalent HPV16 and HPV18 infections as the end-points. For the cross-protected HPV types 31, 33 and 45 statistically significant VE estimates were observed for up to 6 years. For the younger birth cohorts the higher VE estimates may also have included herd effect.
The herd effect estimates derived from the adjusted GEE and the Woolf estimator were both based on the Research Analysis Plan, but the latter was ambiguous regarding the comparison of the gender-neutral and girls-only strategies. The Woolf estimator could not tackle differences in the baseline HPV prevalence rates between the trial arms that remained after randomization but the adjusted GEE method could. According to mathematical models 11, 15, 16 herd effect emerges with a delay, and the HPV prevalence rates continued to decrease from 1992-93 to 1994-95 cohorts. While the adjusted GEE analyses controlled confounding due to variable baseline prevalence rates between trial arms, correlation between non-participation to vaccination and risk-taking behavior threatened to cause another type of bias in Arm C. This was controlled for by sub-sampling the HBV vaccinated participants in Arm C to have equal proportions of HBV vaccinated and non-vaccinated participants in all arms. Our alternative approach, that is, birth cohort-based comparison of prevalence reduction within Arms A or B did not suffer from this bias (Appendix). Both approaches resulted in significant HE estimates for HPV18, HPV31 and HPV33 between Arm A versus Arm C, and within Arm A.
Although the overall vaccination coverage was not more than approximately 50% in females and 20-30% in males our uniform enrolment and high compliance of the adolescent females attending follow-up 12, 22 provided sufficient power for assessing >30% herd effects. 23 The participation of previously non-HPV vaccinated females at the age of 18.5 years was feasible in this school-based trial and also contributed positively to herd effect estimation. Furthermore, both the low to moderate vaccination coverage rates and representative participation of the previously non-HPV vaccinated females at the study end enforce the real-life nature of our trial. Cervicovaginal self-samples rinsed in first void urine were used for HPV DNA testing. The high-throughput PCR method used has been successful in a number of large-scale epidemiological studies. 24 Randomized trial data on the impact of gender-neutral vaccination strategy on HPV18/31/33 is pivotal. Consistent vaccine efficacy, herd effect and protective effectiveness estimates against all the three types were induced by the gender-neutral vaccination in a real-life setting. As for the lack of consistent HPV45 findings, chance cannot be ruled out due to small numbers.
The lack of herd effect against HPV16 can be explained by a high basic reproductive number R0 of HPV16. 25 While other R0 determinants for the different HPV high-risk types are comparable, [26] [27] [28] the clearance rate for HPV16 is two times lower than for the other types. 4, 26, 27, 29 Consequently, the HPV16 prevalence in populations is universally at least twice as high as that of HPV types 18/31/33/45. Thus, even for the gender-neutral vaccination strategy HPV16 was difficult to control by the low to moderate HPV16/18 vaccination coverage. 8, 9, 11, 12, 14 The herd effect-based reduction of HPV16 prevalence in the unvaccinated population apparently needs very high vaccination coverage, as also suggested by surveillance of vaccination programs and models. 8, 9, 14, 16 HPV vaccination is today a globally widespread healthcare policy but current girls-only vaccination programs suffer from low vaccination coverage. 10, 30 Recent modeling work has assessed the direct benefit of vaccinating males, and suggests that gender-neutral vaccination is cost-effective 7 . As a community-randomized trial to measure herd effect and overall protective effectiveness will only be informative if the populations are not vaccinated before, our trial will probably be the only randomized trial ever on the population-level impact of different HPV vaccination strategies. We now demonstrate that gender-neutral vaccination of early adolescents induces significant herd effects and enforces overall protective effectiveness against a number of vaccine-covered high-risk HPV types when low to moderate vaccination coverage apply. 
